Considering-AF
Considering-AF is a randomized, siteless study to compare systematic atrial fibrillation (AF) screening using enrichment by a risk prediction model with standard care in a Swedish population aged from 65 and older.
New method for detecting atrial fibrillation
The aim of the study is to detect atrial fibrillation and prevent blood clots. In the study, all participants need to do is wear an EKG patch for 14 days. None of them currently has a diagnosis of atrial fibrillation. Half of the participants will have their heart activity measured using EKG patches, which will then be compared to the control group.
The goal is to prove that the algorithm used in the study can identify those at the highest risk of atrial fibrillation in the future, enabling early screening and treatment interventions. The randomized controlled trial will test the hypothesis that AF screening in a population with high-risk features, defined by a risk prediction algorithm based on risk factors utilizing a data driven healthcare approach, is superior to standard care in detecting new AF in patients aged ≥ 65 years.
Project time:
The clinical trial started on 4 December and will in May 2024. The project started in 2021 and the analysis will take until Dec 2024.
Partners in the project
- Halmstad University
- Region Halland
- Hallandia V AB
- BMS (Bristol Myers Squibb)
- Pfizer AB and Philips
Funding
CONSIDERING-AF is funded by Bristol Myers Squibb – Pfizer Alliance. ECG patch devices are provided by Philips/BioTel Sweden.
More information
New method for detecting atrial fibrillation tested in Halland (in Swedish)
External link.
Relaterat
Här kan redaktören placera information som kan anses vara relaterad till innehållet på sidan.
